Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model | Zendy

Francisco Campos | Zendy; Tao Qin | Zendy; José Castillo | Zendy; Ji Hae Seo | Zendy; Ken Arai | Zendy; Eng H. Lo | Zendy; Christian Waeber | Zendy

Open Access

Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model

Author(s) -

Francisco Campos,

Tao Qin,

José Castillo,

Ji Hae Seo,

Ken Arai,

Eng H. Lo,

Christian Waeber

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.679043

Subject(s) - fingolimod , medicine , tissue plasminogen activator , stroke (engine) , pharmacology , t plasminogen activator , anesthesia , multiple sclerosis , immunology , mechanical engineering , engineering

The sphingosine 1-phosphate receptor agonist fingolimod reduces infarct size in rodent models of stroke and enhances blood-brain barrier integrity. Based on these observations, we hypothesized that combination of fingolimod with tissue plasminogen activator (tPA) would reduce the risk of hemorrhagic transformation associated with delayed administration of tPA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research